Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

被引：8
|
作者：
Han, Ji Won [1 ,2 ]
Jang, Jeong Won [1 ,2 ]
机构：
[1] Catholic Univ Korea, Catholic Univ Liver Res Ctr, Coll Med, Seoul 06591, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Gastroenterol & Hepatol, Seoul 06591, South Korea
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 14期
基金：
新加坡国家研究基金会;
关键词：
hepatocellular carcinoma; atezolizmumab-bevacizumab; biomarker; NEUTROPHIL-LYMPHOCYTE RATIO; PLUS BEVACIZUMAB; TUMOR; EXPRESSION; CELLS; INTERLEUKIN-6; MULTICENTER; COMBINATION; SUPPRESSION; SORAFENIB;
D O I：
10.3390/ijms241411799
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
A combination of atezolizumab with bevacizumab (AB) is the first regimen that has shown superiority compared to sorafenib and is now being used as the systemic treatment of choice for hepatocellular carcinoma (HCC) patients with Barcelona Liver Cancer Clinic stage C. However, a considerable number of patients do not achieve survival or significant responses, indicating the need to identify predictive biomarkers for initial and on-treatment decisions in HCC patients receiving AB. In this manuscript, we summarized the current data from both experimental and clinical studies. This review will be beneficial for both clinicians and researchers in clinical practice as well as those designing experimental, translational, or clinical studies.
引用
收藏
页数：22
相关论文
共 50 条
  • [1] Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma
    Muto, Hisanori
    Kuzuya, Teiji
    Kawabe, Naoto
    Ohno, Eizaburo
    Funasaka, Kohei
    Nagasaka, Mitsuo
    Nakagawa, Yoshihito
    Miyahara, Ryoji
    Shibata, Tomoyuki
    Hashimoto, Senju
    Katano, Yoshiaki
    Hirooka, Yoshiki
    ANTICANCER RESEARCH, 2023, 43 (10) : 4673 - 4682
  • [2] Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma
    Ochi, Hironori
    Kurosaki, Masayuki
    Joko, Kouji
    Mashiba, Toshie
    Tamaki, Nobuharu
    Tsuchiya, Kaoru
    Marusawa, Hiroyuki
    Tada, Toshifumi
    Nakamura, Shinichiro
    Narita, Ryoichi
    Uchida, Yasushi
    Akahane, Takehiro
    Kondo, Masahiko
    Mori, Nami
    Takaki, Shintaro
    Tsuji, Keiji
    Kusakabe, Atsunori
    Furuta, Koichiro
    Kobashi, Haruhiko
    Arai, Hirotaka
    Nonogi, Michiko
    Tamada, Takashi
    Hasebe, Chitomi
    Izumi, Namiki
    HEPATOLOGY RESEARCH, 2023, 53 (01) : 61 - 71
  • [3] Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol
    Ben Khaled, Najib
    Seidensticker, Max
    Ricke, Jens
    Mayerle, Julia
    Oehrle, Bettina
    Roessler, Daniel
    Teupser, Daniel
    Ehmer, Ursula
    Bitzer, Michael
    Waldschmidt, Dirk
    Fuchs, Martin
    Reuken, Philipp A.
    Lange, Christian M.
    Wege, Henning
    Kandulski, Arne
    Dechene, Alexander
    Venerito, Marino
    Berres, Marie-Luise
    Luedde, Tom
    Kubisch, Ilja
    Reiter, Florian P.
    De Toni, Enrico N.
    FUTURE ONCOLOGY, 2022, 18 (12) : 1423 - 1435
  • [4] Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications
    Lee, Cha Len
    Freeman, Mark
    Burak, Kelly W.
    Moffat, Gordon T.
    O'Donnell, Conor D. J.
    Ding, Philip Q.
    Lyubetska, Hanna
    Meyers, Brandon M.
    Gordon, Vallerie
    Kosyachkova, Ekaterina
    Bucur, Roxana
    Cheung, Winson Y.
    Knox, Jennifer J.
    Tam, Vincent C.
    CANCERS, 2024, 16 (16)
  • [5] Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma
    Kobayashi, Kojiro
    Nagai, Hidenari
    Matsui, Teppei
    Matsuda, Takahisa
    Higai, Koji
    ANTICANCER RESEARCH, 2023, 43 (10) : 4601 - 4609
  • [6] Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
    Maesaka, Kazuki
    Sakamori, Ryotaro
    Yamada, Ryoko
    Tahata, Yuki
    Imai, Yasuharu
    Ohkawa, Kazuyoshi
    Miyazaki, Masanori
    Mita, Eiji
    Ito, Toshifumi
    Hagiwara, Hideki
    Yakushijin, Takayuki
    Kodama, Takahiro
    Hikita, Hayato
    Tatsumi, Tomohide
    Takehara, Tetsuo
    HEPATOLOGY RESEARCH, 2022, 52 (03) : 298 - 307
  • [7] Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
    Brackenier, Cedric
    Kinget, Lisa
    Cappuyns, Sarah
    Verslype, Chris
    Beuselinck, Benoit
    Dekervel, Jeroen
    CANCERS, 2023, 15 (02)
  • [8] Atezolizumab/Bevacizumab in hepatocellular carcinoma
    Kuetting, Fabian
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2020, 26 (10): : 970 - 971
  • [9] Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
    Naganuma, Atsushi
    Kakizaki, Satoru
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hatanaka, Takeshi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishikawa, Hiroki
    Nishimura, Takashi
    Kawata, Kazuhito
    Kosaka, Hisashi
    Hirooka, Masashi
    Yata, Yutaka
    Ohama, Hideko
    Kuroda, Hidekatsu
    Matono, Tomomitsu
    Aoki, Tomoko
    Kanayama, Yuki
    Tanaka, Kazunari
    Tada, Fujimasa
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Nakamura, Shinichiro
    Enomoto, Hirayuki
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    CANCER MEDICINE, 2025, 14 (02):
  • [10] Risk of Variceal Bleeding in Patients Receiving Atezolizumab-Bevacizumab Treatment for Hepatocellular Carcinoma
    Park, Kanghee
    Lee, Hye Won
    Kim, Euichang
    Choi, Won-Mook
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Han, Seungbong
    Choi, Jonggi
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, : 1310 - 1317
12345